A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508359-38-00

Acronym

20230127

Enrollment

Registered

2024-05-31

Start date

2024-08-05

Completion date

Unknown

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early-stage Non-squamous Non-small Cell Lung Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, France, Germany, Italy, Poland, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026